VC Playbook: Making Focus A Strategic Advantage
An Interview With Robert Tansley Of Cambridge Innovation Capital
In this latest installment of In Vivo’s VC Playbook series, Robert Tansley, a partner at Cambridge Innovation Capital, explains the fund’s special arrangement in Cambridge, UK and how the young venture capital group expects to grow in the biotech sector – the imminent prospect of Brexit notwithstanding.
You may also be interested in...
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.